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 2 
Abstract 
 
The liver parenchyma is composed of hepatocytes and bile duct epithelial cells (BECs). 
Controversy exists regarding the cellular origin of human liver parenchymal tissue generation 
during embryonic development, homeostasis or repair. Here we report the existence of a 
hepatobiliary hybrid progenitor (HHyP) population in human foetal liver using single-cell 
RNA sequencing. HHyPs are anatomically restricted to the ductal plate of foetal liver and 
maintain a  transcriptional profile distinct from foetal hepatocytes, mature hepatocytes and 
mature BECs.  In addition, molecular heterogenicity within the EpCAM+ population of freshly 
isolated foetal and adult human liver identifies diverse gene expression signatures of hepatic 
and biliary lineage potential. Finally, we FACS isolate foetal HHyPs and confirm their hybrid 
progenitor phenotype in vivo. Our study suggests that hepatobiliary progenitor cells previously 
identified in mice also exist in humans, and can be distinguished from other parenchymal 
populations, including mature BECs, by distinct gene expression profiles.  
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Introduction 
In rodents both hepatocytes and biliary epithelial cells (BECs) are derived from a common bi-
potent hepatoblast population during liver development1. In adult mice, conflicting evidence 
exists regarding the presence of a distinct bi-potent progenitor capable of regenerating both 
hepatocytes and BECs. The regenerative potential of the rodent liver has been attributed to 
hepatocytes 2, BECs 3,4, biliary-like progenitor cells or ‘oval cells’ arising in the ductal region 
5,6, stem cells located around the central vein 7, and hepatocyte or cholangiocyte de-
differentiation into a hybrid bi-potent progenitor 8,9. In comparison, the mechanisms of human 
liver regeneration are poorly characterised. It has been proposed that EpCAM+ human liver 
stem/progenitor cells reside in the ductal plate (DP) during foetal liver development.  After 
birth these cells localise to the Canals of Hering, where upon severe chronic liver injury they 
become reactivated forming what is pathologically described as ductular reactions 10,11. Despite 
these findings, the existence of a bi-potent human liver ‘progenitor’ cell remains unclear. This 
issue is in part due to a substantial overlap in markers between potential progenitor populations, 
hepatic precursors and mature BECs 3,12,13, challenging the field to define the true 
transcriptional nature of a bi-potent progenitor phenotype that can be replicated for clinical use. 
Several recent studies have captured a bi-potent progenitor-like state via small molecule-
reprogramming of primary hepatocytes, capable of in vitro hepatic and biliary maturation, 
imitating a process that has been observed during chronic mouse liver injury8,14-16. Despite 
several well-established phenotypic criteria for liver progenitor cells, no benchmark exits that 
truly distinguishes them from other human hepatic and biliary cells. To facilitate the in vitro 
development of cell-based therapies for treating liver disease, it is critical to precisely define a 
liver progenitor cell that accurately captures the developmental origin of human liver 
parenchyma. 
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In this study we utilise single cell RNA sequencing (scRNA-seq) to interrogate the 
transcriptome of human foetal and adult liver at single cell resolution. In recent years scRNA-
seq has helped identify unreported cell types within populations previously defined as 
homogenous17-20. Here we report the transcriptional signature of distinct hepatic cell types in 
foetal and adult human liver including a foetal hepatobiliary hybrid progenitor (HHyP) 
population. Capturing a human hepatic progenitor state in utero provides unparalleled and 
unexplored insight into the true mechanisms of human liver development.   We identify a gene 
expression profile that can distinguish between foetal HHyPs, foetal hepatocytes and mature 
BECs. We further identify HHyP-like cells maintained in uninjured adult primary liver tissue. 
Finally, we FACS sorted HHyPs from freshly isolated human foetal liver and show evidence 
of hepatic and biliary phenotypes in vivo. Our in depth profiling of previously undefined 
HHyPs finally provides an accurate template for the human liver progenitor phenotype that 
will be a valuable roadmap for translating ex vivo hepatic progenitor studies into successful 
cell-based liver disease therapies. 
 
Results 
 
 
EpCAM+ cell heterogeneity in human foetal and adult liver by scRNA-seq 
To capture the cellular heterogeneity of human liver during development, we combined a 
FACS strategy with scRNA-seq. We first sorted by negative selection of red blood cells 
(CD235a) and immune cells (CD45), and positively selected for EpCAM and NCAM to enrich 
for potential human liver progenitors 10,21 (Supplementary Figure. 1).  To investigate how foetal 
human liver populations progress into adult liver we isolated and sequenced EpCAM+ (biliary 
cells) and EpCAM-/ASGPR1+ (mature hepatocytes) cells from fresh, uninjured adult tissue 
(Supplementary Figure. 1). In total, 1224 cells were sequenced from human foetal and adult 
livers. Following stringent quality control (qc), 741 cells were retained for downstream 
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analyses (Supplementary Figure. 1) 22. Sample counts were normalised as transcripts per 
million (TPM). 
 
 To define different populations captured by our FACS strategy, we employed t-Distributed 
Stochastic Neighbour Embedding (t-SNE) on high variance genes. We then measured 
differential gene expression to phenotypically characterise the different cell groups (Fig. 1a-
b). We identify several distinct ALB+ cell populations in both the adult and foetal liver single 
cell analysis. As expected by sorting adult human liver cells by EpCAM expression, nearly all 
ASGPR1+ cells are identified as ALB+/ASGR1+/AFP- mature hepatocytes (Supplementary Data 
1). EpCAM+ adult cells express progenitor/BEC markers KRT19 and SOX9 but interestingly 
most are highly ALB+ as well (Fig. 1b-c, Supplementary Data 2).  In foetal liver, two distinct 
ALB+ expressing populations and several non-hepatic populations transcriptionally resembling 
stromal, mesothelial and erythroblast cell types were found (Supplementary Figure. 2). Within 
the ALB+ populations we identified a foetal hepatocyte population expressing hepatoblast 
markers AFP and DLK1, but negative for traditional biliary markers (Fig. 1b-c, Supplementary 
Data 3). Exclusively within the CD235a-/CD45-/EpCAM+/NCAM+ population of human foetal 
liver we identify a cluster of cells that closely resembles EpCAM+ biliary cells identified in 
adult liver, expressing both biliary and hepatic markers which we label here as hepatobiliary 
hybrid progenitor (HHyP) cells  (Fig. 1b-c). Foetal HHyP cells expressed hepatic genes ALB, 
APOE, TF and HNF4A, but were also positive for BEC markers KRT19, SOX9 and CD24 (Fig. 
1c-d, Supplementary Data 4). Having expected to isolate mature BECs from adult EpCAM+ 
cells we looked for expression of mature BEC markers recently identified in a comprehensive 
transcriptomic map of adult human liver 23. We identify a small ALB- population enriched for 
mature BEC markers TFF1 and TFF2. This BEC population is transcriptionally distinct from 
HHyPs which co-express hepatic markers, liver progenitor markers and mature biliary markers 
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(Fig. 1c-d, Supplementary Data 5). Whilst potential BECs in our study share many genes with 
HHyPs from both foetal and adult human liver, they  express a subset of genes enriched in 
mature human BECs captured by scRNA-seq23 (Supplementary Figure. 3). Whilst potential 
BECs in our study share many genes with HHyPs from both foetal and adult human liver, we 
have identified differences in gene expression that can distinguish BECs from HHyPs 
(Supplementary Figure. 3)23. After applying phenotypic labelling to T-SNE analysis we see 
contribution from multiple donors for each cell type, including rarer populations, 
demonstrating the robustness of our data set (Fig. 1e-f).  
 
Populations of hybrid bi-potent progenitors have previously been characterised in mice after 
chronic liver injury8. We therefore compared the transcription profiles of human 
ALB+/KRT19+/KRT7+ HHyPs and ALB-/KRT19+/KRT7+ BECs from our data set with mouse 
hepatocyte-derived proliferative ducts (HepPD) and biliary-derived proliferative ducts (BilPD) 
from Tarlow et al (2014) 8. Relative to their respective biliary populations, human and foetal 
and adult HHyPs have similar expression patterns to HepPDs, identified in mice as having bi-
potent characteristics of liver progenitor cells8. Genes including AHSG, RBP4, SFRP5 and 
MCAM are enriched in both human HHyPs and mouse HePDs, while mature BEC markers 
KRT7, MUC1, TSPAN8  and TFF2 are downregulated in both (Supplementary Figure. 4). Thus 
it is likely that our single cell strategy has captured the existence of a hepatobiliary hybrid 
progenitor population that is transcriptionally distinct from mature BECs and other hepatic cell 
populations but similar to hybrid progenitor cells identified in mice after chronic liver injury.   
 
Identification of a distinct foetal HHyP transcriptional phenotype 
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Further in-depth characterisation of the markers defining different liver populations is required 
to fully understand their role in development and liver regeneration.  Foetal hepatocytes and 
HHyPs demonstrate clear transcriptional distinction. Despite sharing ALB gene expression, 
foetal hepatocytes express none of the traditional progenitor/BEC markers enriched in HHyPs 
including KRT7, SPP1, STAT1, SOX9 and HNF1B. (Fig. 2). Upon t-SNE analysis performed 
only on ALB+ cells from our study, K- means clustering indicates that adult HHyPs are more 
closely associated with adult mature BECs then foetal HHyPs (Fig. 3a). Studies have suggested 
uninjured adult liver would not contain progenitor-like cells with a hybrid hepatobiliary 
phenotype, yet our scRNA-seq analysis on uninjured human adult liver demonstrates HHyPs 
are both present and negative for many recently identified mature human BEC markers23. 
However, despite the high transcriptional similarity between foetal and adult HHyPs there are 
some key differences in gene expression (Fig. 3b). Gene set enrichment analysis (GSEA) on 
foetal HHyP genes enriched over adult identifies ‘Stem cell proliferation’, ‘Developmental cell 
growth’, ‘Homophilic cell adhesion via plasma membrane adhesion molecules’, and 
association with ‘Extracellular matrix component’, suggesting a phenotype associated with 
progenitor/stem cell-like function and important interactions with the niche environment (Fig. 
3c). Genes including TACSTD2 (TROP-2), CLDN4, CLDN10 and KRT7 are enriched in adult 
HHyPs compared to the foetal HHyP population (Fig. 3d). In contrast, expression of CLDN6 
and the transcription factor STAT4 are exclusively detected in foetal HHyPs. MCAM, CDH6 
and STAT1 are also enriched in foetal HHyPs over adult (Fig. 3d).  We observed several other 
interesting gene expression patterns, including GPC3 expressed exclusively in foetal 
parenchymal populations, CXCL2 expressed exclusively in adult parenchymal populations and 
MUC1 restricted to BECs (Fig. 3d). To further understand how foetal HHyPs related to the 
current understanding of liver progenitor cells in the field, we looked at the transcriptome of a 
recent study for human primary hepatocyte-derived liver progenitor-like cells16. We identified 
 8 
that many of the top genes enriched in foetal HHyPs are enriched during the transition process 
from primary hepatocytes to progenitor-like cells including MCAM, ANXA2, ANXA4, BICC1, 
SPIN1, TNFRSF12A, STAT1 and ABCC3 (Fig. 3e). This suggests that in vitro reprogramming 
techniques to create progenitor-like cells from mature hepatocytes are moving towards a foetal 
HHyP-like phenotype. 
 
 TROP-2 expression is restricted to biliary committed cells  
 
To validate the transcriptional signature of HHyP cells we next employed RNA in situ 
hybridization (RNA-ish) and characterised their spatio-temporal regulation in primary human 
foetal tissue. Expression of the HHyP markers CDH6, STAT1, CD24, FGFR2, DCDC2 and 
CTNND2 that we identified are restricted to the ductal plate (a layer of cells surrounding the 
portal tract) in second trimester human foetal liver 24 (Fig. 4a, Supplementary Figure. 5). At 
this stage ALB is expressed highly in the parenchyma but absent from intrahepatic bile ducts 
(Supplementary Figure. 5). We confirmed the hepatic phenotype of ductal plate cells by co-
expression of the ductal plate marker STAT1 with the hepatic marker HNF4A (Supplementary 
Figure. 5). We additionally observed that CDH6 and STAT1 co-localised with the previously 
reported human hepatic stem cell marker CLDN3 and biliary marker SOX9 in the ductal plate 
at the protein level (Fig. 4b, Supplementary Figure. 5) 5,10. Importantly, these markers were 
also expressed within foetal bile ducts (BD) alongside CK19, a classical ductal plate marker 
(Fig. 4c)24. These results highlight a significant challenge to the field, distinguishing between 
potential bi-potent liver progenitors and biliary committed cells which share several markers. 
Our scRNA-seq analysis identified TROP-2 expression to be restricted to adult progenitor/BEC 
cells and absent from foetal HHyPs. Furthermore in Tarlow et al, TROP-2 is expressed in 
bilPDs (biliary progenitors) but not bipotent hepPDs 8. We therefore investigated TROP-2 
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spatial regulation in human foetal liver, as compared to progenitor markers CDH6 and STAT1. 
We observed by RNA-ish that while CDH6 and STAT1 expression were observed in bile ducts 
and the ductal plate progenitor zone, TROP-2 expression was anatomically restricted to bile 
ducts (Fig. 4d). These findings suggest that TROP-2 is up regulated during biliary lineage 
commitment. Therefore TROP-2 is a key marker to distinguish human foetal liver hybrid 
progenitors from TROP-2+ committed BECs present in bile ducts.  
We next investigated whether these in situ findings translated to ex vivo lineage commitment. 
Previous studies have isolated and expanded progenitor-like cells in vitro from the EpCAM+ 
population of human liver in 3-Dimensional culture systems 10,21. We therefore isolated 
EpCAM+ cells from human foetal liver by MACs column purification and generated 3D 
organoids in matrigel suspension (Fig. 4e) 21. As expected, organoids grown in liver expansion 
media were positive for EpCAM, SOX9, CDH6 and HNF4A, suggesting they retained a hybrid 
hepatobiliary phenotype in these conditions (Fig. 5e). To trigger lineage commitment, 
EpCAM+ organoids were transferred to either hepatic or biliary differentiation media 13,25-27,28. 
Consistent with our scRNA-Seq data and in situ staining, organoids became positive for TROP-
2 and CK7 upon transfer to a biliary differentiation media, whereas ALB and HNF4A were not 
expressed. In contrast, organoids transferred to hepatic differentiation media expressed ALB, 
while CDH6, TROP-2 and CK7 were lost in ALB/HNF4A expressing structures (Fig. 4f). 
These findings suggest the expression signature of foetal HHyPs from our scRNA-seq dataset 
can be utilised to distinguish the profile of a human liver progenitor from biliary and hepatic 
committed cells ex-vivo.  
 
Adult HHyPs exhibit gene signatures of both hepatic and biliary lineage 
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Our findings identified distinct human foetal and adult HHyP populations with key differences 
in gene expression. To further investigate heterogenicity within the foetal and adult HHyP 
populations we examined their lineage potential using the R package MONOCLE 29. 
Populations were clustered into 5 ‘pseudo states’ in 2D PCA space (Supplementary Figure. 6). 
Pseudo state 1 contained all foetal HHyPs, and a sub-population of adult HHyPs (blue), 
enriched markers DCDC2, CDH6, STAT1 and ANXA13 (Supplementary Figure. 6).  
Interestingly we observed distinct adult HHyP clusters enriched for either biliary (Pseudo state 
3) or hepatic (Pseudo state 4) lineage markers. Pseudo state 3 revealed an enrichment of ductal 
marker genes KRT7, KRT23, and TROP-2, while hepatic transcription factors ATF5, MLXIPL 
and CREB3L3 were enriched in pseudo state 4 (Supplementary Figure. 6).  
We next looked at the spatial expression of enriched pseudo state 1 markers CDH6, DCDC2 
and ANXA13, alongside STAT1 in adult uninjured liver by in situ hybridization (Supplementary 
Figure. 6). Intriguingly, all markers were expressed in both bile ducts and at the limiting plate 
(LP), an embryonic remnant of the ductal plate surrounding the portal mesenchyme, suggesting 
these cells may be a population intrahepatic duct residing cells distinct from ALB-, 
TFF1+/TFF2+/MUC1+ BECs identified here and in other studies 23. This is further supported 
by our observation that TROP-2 expression is restricted to foetal liver bile ducts and not HHyPs 
localised to the ductal plate (Fig. 4d). TROP-2 has previously been identified in mouse liver 
injury as a marker that distinguishes oval cells from BECs 30, and only expressed in human 
cancers in the liver 31. Therefore, it was important to confirm that TROP-2 is highly expressed 
in the bile ducts of uninjured adult human liver by in situ (Supplementary Figure. 6).  
 
FACS isolation and in vivo transplantation of human foetal liver HHyPs 
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We next looked to assess the intrinsic hepatobiliary lineage potential of distinct foetal human 
liver populations in vivo. We used FACS to isolate distinct foetal hepatic cell populations based 
on their differential surface marker expression, and transplanted each population individually 
underneath the renal capsule of 10 week old NOD scid gamma (NSG) immunodeficient mice 
(Fig. 5a). This approach has previously been used to validate the differentiation potential of 
mouse and human stem cell populations 32-38. We FACS sorted a number of populations to 
investigate their respective in vivo differentiation potential. We isolated CD235a-/CD45-
/EpCAM+/NCAM+/MCAM+ HHyP cells, based on our scRNA-seq analysis of the HHyP 
phenotype (Fig. 5b). As a control we sorted for CD235a-/CD45-/EpCAM+/NCAM-/MCAM- 
cells to assess the in vivo behaviour of non-HHyP EpCAM+ cell types relative to potential 
HHyPs (Fig. 5c). The xenografts were analysed after 4 weeks of development within the kidney 
capsule, and were subsequently assessed by H&E and immunofluorescence staining to 
determine their expansion capabilities and lineage potential. After 4 weeks, only the HHyP cell 
population produced clear expanded regions, despite matched cells numbers transplanted 
between HHyPs and EpCAM+ only populations. Non-transplanted kidney from matched 
samples contained no such explant regions (Fig. 5d).  
We investigated the presence of hybrid progenitor cells within the foetal HHyP explant by 
immunofluorescence (IF) staining of hepatobiliary markers identified in our scRNA-seq 
analysis and validated ex-vivo. IF staining of human-specific ALB and the BEC/progenitor 
marker CK19 within foetal HHyP explant sections revealed the presence of ALB+/CK19+ cells, 
as well as cells expressing only ALB (Fig. 5e). ALB staining was negative in matched mouse 
adult liver control, confirming the presence of human cells in the explant. We next looked at 
markers of hepatic and biliary commitment by IF to assess lineage potential of the FACS sorted 
foetal HHyP population. The hepatic markers Fumarylacetoacetate Hydrolase (FAH) and 
HNF4a are expressed widely across the explant region of HHyP cells confirming the hepatic 
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potential of foetal HHyPs (Fig. 5f). To confirm biliary lineage potential we co-stained HHyP 
explants for ALB and TROP-2, a marker we identified as negative in foetal HHyPs and 
expressed in mature BECs by scRNA-seq analysis.  We identify ALB-/TROP-2+ duct-like 
structures suggesting that the HHyPs population is also capable of producing mature BECs 
(Fig. 5e).  Finally, we also isolated CD235a-/CD45-/EpCAM+/NCAM+/TROP2- cells to enrich 
for HHyPs over biliary lineage committed cells (Fig. 6a-b). As expected few cells were 
captured from foetal CD235a-/CD45-/EpCAM+/NCAM-/TROP2+ population, likely due to 
their restriction to forming bile ducts, thus proving difficult to isolate (Fig. 6c). Again only 
HHyP cell expansion was observed upon renal capsule transplantation over matched control 
cells (EpCAM-/NCAM-/TROP2- cells) or BECs (Fig. 6d). We further show that these cells 
express the FAH, confirming their hepatic lineage potential upon in vivo implantation (Fig. 
6e). Collectively, these results demonstrate the hepatobiliary hybrid phenotype of foetal HHyPs 
identified in our scRNA-seq analysis, as captured previously in mouse chronic liver injury 
studies and small-molecule reprogramming of primary human hepatocytes. 
 
Our FACS and scRNA-seq strategy has captured the transcriptional profile of a HHyP 
population that arises during human foetal liver development. We utilised this profile to clarify 
the strong overlap in markers between potential progenitor populations and mature BECs and 
define a gene signature capable of truly distinguishing liver progenitor cells from mature BEC 
populations.  Integrating our foetal data set with recent scRNA-seq and bulk analysis of 
different hepatic populations, we identify marker sets that exclusively define BEC and 
progenitor populations, as well as markers associated with both 8,16,23. Mature BECs uniquely 
express the genes CLDN10, CLD4, CXCL2, LGALS2, MMP7, MUC1, MUC5B, TROP2, TFF1, 
TFF2, TFF3 and TSPAN8 as determined by our study and MacParland et al (2018) 23 (Fig. 7). 
CLDN4, MMP7, MUC1, TROP-2 and TSPAN8 interestingly are also enriched in mouse BilPDs 
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over HepPDs suggesting a gene signature of biliary specific lineage 8 (Fig. 7). We further 
identified a signature defining human hybrid progenitor cells, distinct from mature BECs, 
immature hepatocytes and mature hepatocytes. Genes including CAV1, CLDN6, GPRC5B, 
MCAM, NCAM and STAT4 are restricted to expression in HHyPs (Fig. 7). Several of these 
genes including MCAM and CAV1 are enriched in bipotent HepPDs that arise in mice after 
chronic liver injury 8. Our study therefore has captured a transcriptional signature of previously 
undefined human foetal HHyPs, comparable to hepatic progenitor-like cells that arise in mice 
during liver injury. 
 
Discussion 
 
In this study, we captured the molecular identity of distinct parenchymal and supporting cell 
populations in both foetal and adult human liver using scRNA-seq. We identified the 
transcriptional signature of a foetal human liver hepatobiliary hybrid progenitor (HHyP) 
population, validated its presence in primary human liver samples, and showed its bi-lineage 
differentiation potential in vivo. In situ, HHyP cells could be anatomically differentiated from 
cholangiocytes/BECs that populate intra-hepatic bile ducts by using markers identified from 
our transcriptional profiling including TROP-2. Our work defines precise transcriptional 
changes during hepatic and biliary lineage commitment and provides evidence to suggest that 
hybrid hepatobiliary progenitor cells previously identified in mice also exist in humans during 
foetal development. 
 
Previous work has proposed human liver stem/progenitors are bi-potent cells capable of 
repopulating both hepatocytes and cholangiocytes/BECs during development and injury 21,39. 
These cells were reported to be EpCAM+/NCAM+, reside in the ductal plate of human foetal 
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liver and be retained in the Canals of Herring of normal adult livers 10,40.  Transcriptionally, 
they co-express genes associated with both hepatic and biliary lineage. Recent studies have 
captured similar hybrid-like liver progenitor cells in mouse and human adult liver tissue. In 
mouse, bi-potent progenitors have been traced from chronically injured hepatocytes8 and 
mature BECs3,4.  In humans, hepatocyte trans-differentiation post-injury gives rise to hybrid 
cells41. Finally, in vitro small-molecule reprogramming of both mouse and human mature adult 
primary hepatocytes can generate a population of proliferating bipotent liver progenitor cells14-
16. Despite validating their in vivo efficacy, little effort has been put into understanding the 
developmental origin of human liver progenitor cells and therefore how physiologically 
relevant they may be in a clinical setting. Using scRNA-seq, we identified cells with hybrid 
hepatobiliary characteristics within the human foetal liver EpCAM+/NCAM+ FACS 
population. These cells transcriptionally resemble the periportal hybrid progenitors previously 
identified in mice, being positive for SOX9, HNF1B  and KRT19, but also ALB, APOE and TF 
6,8,9. HNFA expression was also confirmed by in situ mRNA staining. They also express 
BEC/progenitor markers CD24, CD133, CLDN3, FGFR2, KRT7 and SPP1. How these hybrid 
cells arise is contentious, having been previously attributed to hepatocyte plasticity 2,8, 
cholangiocyte trans-differentiation 4,9 or representative of a quiescent undifferentiated / reserve 
state in uninjured post-natal liver 6,10.  
 
We found that HHyPs were distinct from foetal hepatoblasts which are AFP+/DLK+. 
Interestingly, recent scRNA-seq data on mouse liver was used to propose that hepatocyte and 
cholangiocyte lineages originate from AFP+/DLK+ hepatoblasts, and not from HHyPs42. 
However, the authors positively selected for DLK expressing cells, and therefore excluded 
EpCAM+/DLK- cells we identified. This cell capture strategy may explain the discrepancy with 
our results. Our cell-sorting protocol on the other hand is likely enriching for progenitors. 
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Accordingly, we captured only a very limited number of mature ALB-/SOX9+/KRT7+ BECs. 
Intriguingly, our sorting strategy isolated a population of EpCAM+ cells highly similar to foetal 
HHyPs, expressing hepatic markers ALB, HNF4A, RBP4 and biliary markers SOX9, KRT19 
and KRT7. However, these cells were negative for mature BEC markers identified in the recent 
MacParland et al (2019) scRNA-seq study of human liver, including Trefoil factors (TFF)1-3 
and mucins MUC1, MUC3A and MUC5B23. This study however, also identified ALB 
expression in a subpopulation of BECs 23. This raises the possibility that adult HHyPs identified 
in our study may indeed represent a population of mature BECs distinct from ALB-
/TFF1+/TFF2+/TFF3+ BECs. TFFs have been previously reported to be heterogeneously 
expressed across different intrahepatic bile ducts43,44. Furthermore, it has recently been 
reported that adult mice bile ducts contain distinct BEC populations with differing proliferative 
capabilities 45. Our findings suggest thus could be interpreted as revealing BEC heterogenicity 
in healthy liver. It is possible that these populations and the mechanisms that govern their 
behaviour regulate the inherent plasticity of parenchymal cell populations towards mature 
hepatic and biliary lineage in response to injury 4,8,14,15,41,46. A key difference between foetal 
and adult HHyPs is the expression of TROP-2, also expressed in mature BECs. TROP-2 is a 
closely related family member of EpCAM thought to be absent or weakly expressed in normal 
liver tissue and enriched only at times of injury 30 or cancer 31. Our data clearly show this is not 
the case in humans, with TROP-2 being expressed in adult bile ducts during normal 
homeostasis. Our data further suggests that TROP-2 expression marks HHyP commitment 
towards biliary lineage, consistent with recent mouse data8. While this supports the notion that 
we have captured distinct populations of adult BECs, our analysis also confirms that adult 
HHyPs are transcriptionally close to foetal HHyPs validated in vivo for lineage potential and 
mouse ‘oval cells’. Therefore we cannot say conclusively that these cells are a specific mature 
BEC population without further functional validation, a collective problem the field of human 
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liver progenitor studies faces. It is likely however that, these populations respond differently 
to different injury stimuli. Understanding the phenotypes of distinct biliary populations is 
important when considering that the management of hepatic diseases is often hindered by 
difficulties in identifying their cellular origin. Given the frequent overlap in markers between 
multiple parenchymal cell types, it is crucial to accurately determine new histological markers.  
 
Using the renal capsule of immunodeficient mice we demonstrate the proliferative and 
hepatobiliary hybrid lineage potential of freshy isolated foetal human HHyPs. Investigating 
true functional stemness of freshly isolated progenitor cells for clonality, bi-potency and rescue 
was unfeasible in this study due to the low cell numbers obtained post FACS sorting from rare 
human tissue. Recent studies focused on the translational potential of progenitor cells for liver 
repopulation required ex vivo expansion to produce sufficiently high numbers for 
transplantation into multiple animals, injured with enough severity such that an environment 
conducive to engraftment of donor cells is induced10,21,40,47. To avoid physiological variables 
that compound this approach, we elected to implant cells directly after FACS to experimentally 
match cells we assayed in vivo with those defined through scRNA-seq. This approach also 
completely removes results obtained as a consequence of ex vivo culture. We chose therefore, 
to implant the foetal HHyP cell population into a non-hepatic space previously reported to be 
permissive for evaluation of the developmental potential of small numbers of human cells. 
32,33,37,48,49. While this assay limits the functional validation of HHyP clonality and functional 
bi-potency of liver injury studies, this allowed us to investigate proliferative and hepatobiliary 
lineage potential of well-defined and freshly isolated rare human liver progenitor populations 
without in vitro expansion prior to transplantation10,21,40,47,50. Using this approach we show that 
foetal HHyPs within the EpCAM+/NCAM+ FACS population previously shown to harbour 
human foetal progenitor cells10, are capable of expanding into FAH and HNF4A expressing 
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hepatocytes within the kidney capsule environment. Specifically, EpCAM+/NCAM+/MCAM+ 
FACS isolated human foetal liver HHyPs were capable of expansion within the renal capsule, 
and shown to be ALB+/CK19+ confirming the hepatobiliary hybrid phenotype of this 
population. Cells isolated from EpCAM+/NCAM- foetal human livers did not engraft 
efficiently beneath the renal capsule. Our scRNA-seq analysis predicts this population is likely 
enriched for foetal immature hepatocytes, and may reflect their inability to expand in this niche. 
In our scRNA-seq analysis MCAM is identified as specifically enriching the foetal and adult 
HHyP phenotype, absent from expression in mature TTF1/TTF2/TTF3+ BEC populations and 
from foetal hepatocytes. Furthermore, in mouse chronic liver injury studies, MCAM is 
enriched in hepatocyte derived proliferative ducts, over those derived from mature BECs 
alongside AHSG, ALB, CAV1 and RBP48.  Interestingly, MCAM (CD146) has previously been 
reported to be expressed on hepatic stellate cells that closely interact with human hepatic stem 
cells, as well as many different cell types including aggressive epithelial cancers10,51,52. MCAM 
forms homotypic cell-cell interactions and therefore may play a key role in the niche-progenitor 
interface and regulating the interactions of foetal HHyPs with cells that comprise the stem cell 
niche during human liver development. Our in vivo findings validate our initial transcriptional 
labeling of FACS isolated putative foetal liver progenitors as hepatobiliary in  nature. It will 
be of great interest for future research to investigate the presence of an expanded HHyP 
phenotype in human hepatobiliary disease tissue for fresh isolation in greater cell numbers to 
more specifically address questions on clonality, bi-potency and functional rescue potential .  
 
Previous attempts to address fundamental questions surrounding the presence and nature of 
liver stem/progenitors have been hampered by the lack of correlation between mouse and 
human models and the limited resolution of lineage tracing strategies. By contrast, the 
combination of carefully selected human tissue and single cell analysis performed here has 
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facilitated the identification of a hybrid progenitor population from human foetal liver. 
Furthermore, these cells are transcriptionally distinct from mature human BECs. In our study 
we present an accurate gene expression profile of human foetal liver progenitor cells that the 
field can benchmark against for a biologically relevant phenotype. In-depth characterization of 
the mechanisms regulating the behaviour of hepatobiliary hybrid progenitor population will 
help advance our understanding of human liver development and disease.  
 
Methods 
 
ScRNA-seq cell sorting and cDNA library preparation. 
All human tissues were collected with informed consent following ethical and institutional 
guidelines (Stanford, US and Kings College London, UK). Freshly isolated adult hepatocytes 
were obtained from Triangle Research Labs, while foetal livers were obtained from the Human 
Developmental Biology Resource of University College London. Human foetal tissue was 
dissociated by Collagenase XI enzymatic dissociation for 25 minutes at 37˚C with agitation. 
Samples were stained with the following primary antibodies, CD235a (349104, FITC, mouse; 
Biolegend), CD45 (304050, BV711, mouse; Biolegend), EpCAM (324208, APC, mouse; 
Biolegend), NCAM (362524, PE, mouse; Biolegend), ASGPR1 (563655, PE, mouse, BD 
Pharmingen™), TFRC (334106, PE mouse, 1:100; Biolegend), MCAM (361005, PE, mouse; 
Biolegend), TACSTD2 (363803, PE, mouse; Biolegend) all at 1:100 dilution and incubated for 
30mins at 4˚C. DAPI (D1306, ThermoFisher Scientific) at 1:1000 dilution was used for 
live/dead staining. Single-cell sequencing was performed using SmartSeq253. Briefly, cells 
were sorted using a BD FACS Aria II instrument and deposited as single cells into 96-well 
plates, pre-loaded with lysis buffer (1% Triton X-100, 1mM dNTP, 1µM oligo-dT30, 
1:1.2x106 ERCC ExFold RNA spike-in, Recombinant RNase Inhibitor (2313B, Takara 
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Clontech). RNA was converted into cDNA using SMARTScribe Reverse Transcriptase 
(639538, Takara Clontech) and amplified for 21 cycles (Kapa HiFi HotStart ReadyMix 2x, 
KK2602, KAPA Biosystems). Successful single cell libraries were identified by capillary gel 
electrophoresis (DNF-474-1000, High Sensitivity NGS Fragment Analysis Kit, AATI) and 
converted into sequencing libraries using a Nextera XT DNA Sample Preparation Kit (FC-131-
1096, Illumina). Barcoded libraries were pooled and subjected to 75 base pair paired-end 
sequencing on a Illumina NextSeq 2500 instrument.  
 
 
DNA sequencing and analysis of single-cell transcriptomes 
Raw sequencing reads were aligned using STAR and per gene counts were calculated using 
HTSEQ 54,55. Gene counts were further analyzed using the R package SCATER for pre-
processing, quality control and normalization22. To filter out unsuitable cells for scRNA-seq 
analysis we used median absolute deviations (MADs) on library size, total genes detected, 
mitochondrial gene percentage and artificial ERCC spike in percentage. Two deviations from 
the median were used to remove cell outliers. For library size and total genes the lower tail 
outliers were excluded. For mitochondrial and ERCC spike in percentage upper tail outliers 
were excluded. T-SNE, spearman’s ranks co-efficient, hierarchical clustering, and Student’s t 
tests were performed using custom scripts in R. T-SNE was performed on log10(TPM) 
normalized gene counts. For t-SNE analysis, the top 1000 variable features were used between 
all cells in the analysis. User-defined K-means clustering was performed in R. Optimal number 
of clusters was determined by peak cluster stability with silhouette analysis in R. For 
differential gene expression 1.50 fold change and p-value < 0.05 was used as a cut off 
determined by student t-test. Gene set enrichment analysis (GSEA) was performed on 
normalized scRNA-seq gene expression data through GSEA software run using the ‘GO 
 20 
TERM’ collection 56. Pseudo lineage and lineage trajectory analysis was performed in R using 
the MONOCLE package 29 .    
 
In Situ RNA Hybridization  
Foetal and adult human liver samples were fixed in 10% formalin buffer saline (HT501128, 
Sigma Aldrich) for two days then dehydrated and paraffin wax infiltrated using Excelsior™ 
AS Tissue Processor. After embedding, sections (5µm) were processed for In Situ RNA 
Hybridization RNA-ISH  using  the  RNAscope  2.5 High Definition (Red, 322350 ACD Bio) 
according to the manufacturers instructions. For single-plex staining the following probes were 
used; CDH6 (Hs-CDH6 403011), TACSTD2 (Hs-TACSTD2 405471), DCDC2 (HS-DCDC2 
452911), ANXA13 (HS-ANXA13 542811), HNF4A (HS-HNF4A 442921), CD24 (HS-CD24 
313021), CTNND2 (HS-CTNND2, custom), FGFR2 (Hs-FGFR2, 311171), (All ACD Bio). 
For Duplex RNA-ISH for transcript expression was performed using RNAscope® 2.5 HD 
Duplex Assay (322435, ACD Bio) according to manufacturer’s instructions using the 
following custom probes; STAT1 (Hs-STAT1 469861, C2 channel change). Slides were 
counterstained with H&E QS (Vector Laboratories. Inc. Mounted slides were imaged using 
NanoZoomer (Hamamatsu).  
 
Tissue processing and analysis for IF and IHC 
For IF staining, foetal liver samples were OCT (23-730-571, ThermoFisher Scientific) 
embedded, sectioned (5µm) and fixed for 10 minutes in 4% w/v PFA. Primary antibodies were 
used at the indicated dilutions: CDH6 (AF2715, sheep, 1:50; RnD systems), CLAUDIN-3 
(83609S, rabbit, 1:50, Cell Signalling), SOX9 (AF3075, goat, 1:100, RnD systems) and STAT1 
(610115, mouse, 1:100; Transduction laboratories) at 4˚C overnight. Cells were incubated 
Alexa 647, Alexa 568, Alexa 488 conjugated secondary antibodies (all Life Technologies) and 
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counterstained with DAPI (D1306, ThermoFisher Scientific). Images were acquired with a 
Nikon A1 confocal microscope (Nikon Instruments Inc.). Digital images were processed using 
NIS elements Advanced Research (Nikon) or ImageJ (https://imagej.nih.gov/ij/). 
 
IHC – Tissue sections  
Paraffin-embedded foetal liver tissue was prepared as described for RNA-ISH. After 
embedding, sections (5µm) were stained using mouse and rabbit specific HRP/AEC (ABC) 
Detection IHC Kit (abcam) using antibodies against EpCAM (ab7504, mouse, 1:100; abcam), 
CK19 (ab52625, rabbit, 1:200; abcam), CDH6 (ABIN950438, mouse, 1:100; Antibodies 
online) and STAT1 (610115, mouse, 1:100; Transduction laboratories) then counterstained 
with Eosin Y dye (ab146325, abcam). Mounted slides were imaged using a NanoZoomer 
(Hamamatsu). 
 
EpCAM+ foetal liver cell isolation 
Dissociated and filtered foetal liver cells were incubated with anti-CD326 (EpCAM) 
MicroBeads (130-061-101, Miltenyl Biotech) in 0.5 % BSA with 5U/ml DNASE1 (M0303, 
N.E.B) and passed through a large cell separation column 2x (130-042-202, miltenyl biotech). 
Total, EpCAM enriched and EpCAM depleted populations were FACS analyzed for CD235a 
and EpCAM on a BD Fortessa cell analyzer. For foetal liver intra-hepatic organoid formation 
(f-IHO) EpCAM enriched cells were pelleted at 300 × g for 5 minutes. The cell pellet was 
resuspended in a Matrigel® (354230 , Corning) dome containing ~50,000 cells/dome in one 
well of a 48-well plate covered in 250µl of LE media. Media was changed every 48h.  
 
Organoid culture conditions 
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Liver expansion (LE) media was based on DMEM/F-12, GlutaMAX™ (10565018, Gibco, life 
technologies) supplemented with 1% N2 supplement (17502048, Gibco, life technologies), 2% 
B27 supplement (17504044, Gibco, life technologies), 20 mM HEPES (15630080, Gibco, Life 
technologies), 1.25 mM N-Acetylcysteine (A7250, Sigma), 1% penicillin-streptomycin 
(15140122, Sigma Aldrich), 1% Insulin:Transferrin:Selenium (ITS) (41400045, Gibco, life 
technologies),  and the growth factors: 50 ng/ml EGF (AF-100-15 , Peprotech),  500 ng/ml 
RSPO1 (120-38 , Peprotech), 100 ng/ml FGF10 (100-26, Peprotech), 25 ng/ml HGF (00-39, 
Peprotech), 10 mM Nicotinamide (72340, Sigma), 25 µM RepSox (3742, Tocris), 10 µM 
Forskolin (1099, Tocris), 0.1 µM dexamethasone (1126, R&D Systems),  25 ng/ml Noggin 
(120-10C, Peprotech), 1:100 Wnt3a (homemade, described in 57, and 10 µM Y27632. Hepatic 
differentiation (HD) media was based on DMEM/F-12, GlutaMAX™ supplement 
supplemented with 20 mM HEPES, 1.25 mM N-Acetylcysteine (A7250, Sigma), 1% 
penicillin-streptomycin (15140122, Sigma Aldrich), 1% ITS, 0.1 µM dexamethasone, 10 µM 
Y27632, 25 ng/ml HGF (00-39, Peprotech), 10 µM DAPT (D5942, Sigma), 2ng/ml Oncostatin-
M (295-OM-050, Bio-Techne) and 10ng/ml BMP4 (314-BP-010, Bio-Techne). Biliary 
differentiation (BD) media was based on DMEM/F-12, GlutaMAX™ supplement 
supplemented with 20 mM HEPES, 1.25 mM N-Acetylcysteine (A7250, Sigma), 1% 
penicillin-streptomycin (15140122, Sigma Aldrich), 1% ITS, 0.1 µM dexamethasone, 10 µM 
Y27632, 50 ng/ml EGF, 500 ng/ml RSPO1 and 100 ng/ml DKK-1 (5439-DK, R&D systems), 
3µM Retinoic acid R2625, Sigma) and 10ng/ml Activin-A (ActA, Q-kine). The culture 
medium was changed every 48 hours.  
 
Passaging and staining organoids 
To split f-IHOs, Matrigel® was digested with Trypsin-EDTA for 15 minutes at 37 °C. Cell 
suspension was centrifuged at 300g for 4 minutes, washed once with William's E medium and 
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resuspended in Matrigel® domes as described above. Organoids were typically passaged at a 
1:4 ratio. For IF staining of organoids, Matrigel® was dissolved in cell recovery solution 
(11543560, ThermoFischer scientific) for 30 minutes at 4˚C and fixed for 30 minutes in 4% 
w/v PFA. Blocking was performed for 1h in 3% donkey serum, 0.3% Triton and 0.1% DMSO.  
Primary antibodies were used 4˚C overnight at the indicated dilutions: CDH6 (AF2715, sheep, 
1:50; RnD systems), EPCAM (ab7504, mouse, 1:100; abcam), KRT7 (ab9021, mouse, 1:100; 
abcam), HNF4A (ab92378, rabbit, 1:100; abcam), CK19 (ab52625, rabbit, 1:200; abcam), 
albumin (A80-129A, goat, 1:100; Bethyl), TROP2 (10428-MM02, mouse,  1:100; Stratech). 
DAPI was used at 1:1000 dilution as a counterstain. Alexa Fluor-conjugated secondary 
antibodies (all 1:500, Life Technologies). Images were acquired with a Nikon A1 inverted 
confocal microscope, a Nikon Ti spinning disk confocal microscope (Nikon Instruments Inc.) 
and a Leica TCS SP8 microscope (Leica Biosystems). 
 
In vivo transplantation of cells 
All experiments were performed in accordance with UK laws (Animal [Scientific Procedures] 
Act 1986) with approval of local ethics committee (King’s college Animal Welfare and Ethical 
Review Board, London, UK) under a Home Office approved project licence. HHyPs or other 
foetal human liver cells were purified using FACS, resuspended in 20	ul of Matrigel and then 
injected using a Hamilton syringe underneath the renal capsule of 10—11 week-old 
immunodeficient NSG mice. Injected cells developed into a graft. The grafts were surgically 
removed for analysis after 4 weeks. 
 
IF staining of human xenografts 
After surgical removal human cell renal capsule grafts were fixed in 10% formalin buffer saline 
for 12 hours with rotation, washed 3x in PBS then dehydrated and paraffin wax infiltrated using 
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Excelsior™ AS Tissue Processor. For IF staining, antigen retrieval was performed for 20 
minutes in 1x citrate buffer pH 6.0 (C9999, Sigma Aldrich). Specimens were permeabilised in 
0.1% Triton in 1% BSA solution for 1h, and blocked in 10% Donkey serum, 1% BSA in PBS 
for 2h. Primary antibodies were used 4˚C overnight at the indicated dilutions: FAH (20-0042, 
rabbit, 1:100; Yecuris) CK19 (602-670, rabbit, 1:100; Abbomax), albumin (A80-129A, goat, 
1:100; Bethyl), TROP2 (10428-MM02, mouse,  1:100; Stratech), HNF4A (ab92378, rabbit, 
1:100; abcam). DAPI was used at 1:1000 dilution as a counterstain. Alexa Fluor-conjugated 
secondary antibodies (all 1:500, Life Technologies). Images were acquired with a Lecia DM6B 
upright microscope (Leica Biosystems). 
 
Data Availability: 
The authors declare that all data supporting the findings of this study are available within the 
article and its supplementary information files or from the corresponding author upon 
reasonable request. 
Raw RNA-seq data have been deposited in the Gene Expression Omnibus (GEO) database 
under accession code GSE130473.  
 
 
 
 
 
 
 
 
 
 25 
 References:  
1 Lemaigre, F. & Zaret, K. S. Liver development update: new embryo models, cell lineage 
control, and morphogenesis. Curr Opin Genet Dev 14, 582-590, 
doi:10.1016/j.gde.2004.08.004 (2004). 
2 Yanger, K. et al. Adult hepatocytes are generated by self-duplication rather than stem 
cell differentiation. Cell Stem Cell 15, 340-349, doi:10.1016/j.stem.2014.06.003 
(2014). 
3 Lu, W. Y. et al. Hepatic progenitor cells of biliary origin with liver repopulation capacity. 
Nat Cell Biol 17, 971-983, doi:10.1038/ncb3203 (2015). 
4 Raven, A. et al. Cholangiocytes act as facultative liver stem cells during impaired 
hepatocyte regeneration. Nature 547, 350-354, doi:10.1038/nature23015 (2017). 
5 Furuyama, K. et al. Continuous cell supply from a Sox9-expressing progenitor zone in 
adult liver, exocrine pancreas and intestine. Nat Genet 43, 34-41, doi:10.1038/ng.722 
(2011). 
6 Font-Burgada, J. et al. Hybrid Periportal Hepatocytes Regenerate the Injured Liver 
without Giving Rise to Cancer. Cell 162, 766-779, doi:10.1016/j.cell.2015.07.026 
(2015). 
7 Wang, B., Zhao, L., Fish, M., Logan, C. Y. & Nusse, R. Self-renewing diploid Axin2(+) 
cells fuel homeostatic renewal of the liver. Nature 524, 180-185, 
doi:10.1038/nature14863 (2015). 
8 Tarlow, B. D. et al. Bipotential adult liver progenitors are derived from chronically 
injured mature hepatocytes. Cell Stem Cell 15, 605-618, 
doi:10.1016/j.stem.2014.09.008 (2014). 
9 Deng, X. et al. Chronic Liver Injury Induces Conversion of Biliary Epithelial Cells into 
Hepatocytes. Cell Stem Cell 23, 114-122.e113, doi:10.1016/j.stem.2018.05.022 (2018). 
10 Schmelzer, E. et al. Human hepatic stem cells from fetal and postnatal donors. J Exp 
Med 204, 1973-1987, doi:10.1084/jem.20061603 (2007). 
11 Lowes, K. N., Brennan, B. A., Yeoh, G. C. & Olynyk, J. K. Oval cell numbers in human 
chronic liver diseases are directly related to disease severity. Am J Pathol 154, 537-
541, doi:10.1016/S0002-9440(10)65299-6 (1999). 
12 Yovchev, M. I., Grozdanov, P. N., Joseph, B., Gupta, S. & Dabeva, M. D. Novel hepatic 
progenitor cell surface markers in the adult rat liver. Hepatology 45, 139-149, 
doi:10.1002/hep.21448 (2007). 
13 Sampaziotis, F. et al. Cholangiocytes derived from human induced pluripotent stem 
cells for disease modeling and drug validation. Nat Biotechnol 33, 845-852, 
doi:10.1038/nbt.3275 (2015). 
14 Kim, Y. et al. Small molecule-mediated reprogramming of human hepatocytes into 
bipotent progenitor cells. J Hepatol 70, 97-107, doi:10.1016/j.jhep.2018.09.007 
(2019). 
15 Katsuda, T. et al. Conversion of Terminally Committed Hepatocytes to Culturable 
Bipotent Progenitor Cells with Regenerative Capacity. Cell Stem Cell 20, 41-55, 
doi:10.1016/j.stem.2016.10.007 (2017). 
16 Fu, G. B. et al. Expansion and differentiation of human hepatocyte-derived liver 
progenitor-like cells and their use for the study of hepatotropic pathogens. Cell Res 
29, 8-22, doi:10.1038/s41422-018-0103-x (2019). 
 26 
17 Treutlein, B. et al. Reconstructing lineage hierarchies of the distal lung epithelium 
using single-cell RNA-seq. Nature 509, 371-375, doi:10.1038/nature13173 (2014). 
18 Darmanis, S. et al. Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the 
Migrating Front of Human Glioblastoma. Cell Rep 21, 1399-1410, 
doi:10.1016/j.celrep.2017.10.030 (2017). 
19 Philippeos, C. et al. Spatial and Single-Cell Transcriptional Profiling Identifies 
Functionally Distinct Human Dermal Fibroblast Subpopulations. J Invest Dermatol, 
doi:10.1016/j.jid.2018.01.016 (2018). 
20 Proserpio, V. et al. Single-cell analysis of CD4+ T-cell differentiation reveals three 
major cell states and progressive acceleration of proliferation. Genome Biol 17, 103, 
doi:10.1186/s13059-016-0957-5 (2016). 
21 Huch, M. et al. Long-term culture of genome-stable bipotent stem cells from adult 
human liver. Cell 160, 299-312, doi:10.1016/j.cell.2014.11.050 (2015). 
22 McCarthy, D. J., Campbell, K. R., Lun, A. T. & Wills, Q. F. Scater: pre-processing, quality 
control, normalization and visualization of single-cell RNA-seq data in R. 
Bioinformatics 33, 1179-1186, doi:10.1093/bioinformatics/btw777 (2017). 
23 MacParland, S. A. et al. Single cell RNA sequencing of human liver reveals distinct 
intrahepatic macrophage populations. Nat Commun 9, 4383, doi:10.1038/s41467-
018-06318-7 (2018). 
24 Terada, T. Ductal plate in hepatoblasts in human fetal livers: I. ductal plate-like 
structures with cytokeratins 7 and 19 are occasionally seen within human fetal 
hepatoblasts. Int J Clin Exp Pathol 6, 889-896 (2013). 
25 Huch, M. et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven 
regeneration. Nature 494, 247-250, doi:10.1038/nature11826 (2013). 
26 Fan, J. et al. Bone morphogenetic protein-4 induced rat hepatic progenitor cell (WB-
F344 cell) differentiation toward hepatocyte lineage. J Cell Physiol 220, 72-81, 
doi:10.1002/jcp.21731 (2009). 
27 Clotman, F. et al. Control of liver cell fate decision by a gradient of TGF beta signaling 
modulated by Onecut transcription factors. Genes Dev 19, 1849-1854, 
doi:10.1101/gad.340305 (2005). 
28 Sampaziotis, F. et al. Reconstruction of the mouse extrahepatic biliary tree using 
primary human extrahepatic cholangiocyte organoids. Nat Med 23, 954-963, 
doi:10.1038/nm.4360 (2017). 
29 Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by 
pseudotemporal ordering of single cells. Nat Biotechnol 32, 381-386, 
doi:10.1038/nbt.2859 (2014). 
30 Okabe, M. et al. Potential hepatic stem cells reside in EpCAM+ cells of normal and 
injured mouse liver. Development 136, 1951-1960, doi:10.1242/dev.031369 (2009). 
31 Cubas, R., Li, M., Chen, C. & Yao, Q. Trop2: a possible therapeutic target for late stage 
epithelial carcinomas. Biochim Biophys Acta 1796, 309-314, 
doi:10.1016/j.bbcan.2009.08.001 (2009). 
32 Chan, C. K. et al. Identification and specification of the mouse skeletal stem cell. Cell 
160, 285-298, doi:10.1016/j.cell.2014.12.002 (2015). 
33 Chan, C. K. F. et al. Identification of the Human Skeletal Stem Cell. Cell 175, 43-56.e21, 
doi:10.1016/j.cell.2018.07.029 (2018). 
 27 
34 Zhu, F. et al. A modified method for implantation of pluripotent stem cells under the 
rodent kidney capsule. Stem Cells Dev 23, 2119-2125, doi:10.1089/scd.2014.0099 
(2014). 
35 van den Berg, C. W. et al. Renal Subcapsular Transplantation of PSC-Derived Kidney 
Organoids Induces Neo-vasculogenesis and Significant Glomerular and Tubular 
Maturation In Vivo. Stem Cell Reports 10, 751-765, doi:10.1016/j.stemcr.2018.01.041 
(2018). 
36 Hentze, H. et al. Teratoma formation by human embryonic stem cells: evaluation of 
essential parameters for future safety studies. Stem Cell Res 2, 198-210, 
doi:10.1016/j.scr.2009.02.002 (2009). 
37 Leong, K. G., Wang, B. E., Johnson, L. & Gao, W. Q. Generation of a prostate from a 
single adult stem cell. Nature 456, 804-808, doi:10.1038/nature07427 (2008). 
38 Hannan, N. R. et al. Generation of multipotent foregut stem cells from human 
pluripotent stem cells. Stem Cell Reports 1, 293-306, 
doi:10.1016/j.stemcr.2013.09.003 (2013). 
39 Schmelzer, E., Wauthier, E. & Reid, L. M. The phenotypes of pluripotent human hepatic 
progenitors. Stem Cells 24, 1852-1858, doi:10.1634/stemcells.2006-0036 (2006). 
40 Turner, R. et al. Human hepatic stem cell and maturational liver lineage biology. 
Hepatology 53, 1035-1045, doi:10.1002/hep.24157 (2011). 
41 Schaub, J. R. et al. De novo formation of the biliary system by TGFβ-mediated 
hepatocyte transdifferentiation. Nature 557, 247-251, doi:10.1038/s41586-018-0075-
5 (2018). 
42 Yang, L. et al. A single-cell transcriptomic analysis reveals precise pathways and 
regulatory mechanisms underlying hepatoblast differentiation. Hepatology 66, 1387-
1401, doi:10.1002/hep.29353 (2017). 
43 Sasaki, M., Ikeda, H., Ohira, S., Ishikawa, A. & Nakanuma, Y. Expression of trefoil factor 
family 1, 2, and 3 peptide is augmented in hepatolithiasis. Peptides 25, 763-770, 
doi:10.1016/j.peptides.2003.12.023 (2004). 
44 Sasaki, M. et al. Site-characteristic expression and induction of trefoil factor family 1, 
2 and 3 and malignant brain tumor-1 in normal and diseased intrahepatic bile ducts 
relates to biliary pathophysiology. Liver Int 24, 29-37, doi:10.1111/j.1478-
3231.2004.00883.x (2004). 
45 Li, B. et al. Adult Mouse Liver Contains Two Distinct Populations of Cholangiocytes. 
Stem Cell Reports 9, 478-489, doi:10.1016/j.stemcr.2017.06.003 (2017). 
46 Tanimizu, N. et al. Progressive induction of hepatocyte progenitor cells in chronically 
injured liver. Sci Rep 7, 39990, doi:10.1038/srep39990 (2017). 
47 Dan, Y. Y. et al. Isolation of multipotent progenitor cells from human fetal liver capable 
of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 103, 
9912-9917, doi:10.1073/pnas.0603824103 (2006). 
48 Zhao, T. et al. Humanized Mice Reveal Differential Immunogenicity of Cells Derived 
from Autologous Induced Pluripotent Stem Cells. Cell Stem Cell 17, 353-359, 
doi:10.1016/j.stem.2015.07.021 (2015). 
49 Boyd, A. S. & Wood, K. J. Characteristics of the early immune response following 
transplantation of mouse ES cell derived insulin-producing cell clusters. PLoS One 5, 
e10965, doi:10.1371/journal.pone.0010965 (2010). 
 28 
50 Nowak, G. et al. Identification of expandable human hepatic progenitors which 
differentiate into mature hepatic cells in vivo. Gut 54, 972-979, 
doi:10.1136/gut.2005.064477 (2005). 
51 Aldovini, D. et al. M-CAM expression as marker of poor prognosis in epithelial ovarian 
cancer. Int J Cancer 119, 1920-1926, doi:10.1002/ijc.22082 (2006). 
52 Wu, Z. et al. MCAM is a novel metastasis marker and regulates spreading, apoptosis 
and invasion of ovarian cancer cells. Tumour Biol 33, 1619-1628, doi:10.1007/s13277-
012-0417-0 (2012). 
53 Picelli, S. et al. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc 9, 
171-181, doi:10.1038/nprot.2014.006 (2014). 
54 Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21, 
doi:10.1093/bioinformatics/bts635 (2013). 
55 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
throughput sequencing data. Bioinformatics 31, 166-169, 
doi:10.1093/bioinformatics/btu638 (2015). 
56 Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for 
interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-
15550, doi:10.1073/pnas.0506580102 (2005). 
57 Willert, K. et al. Wnt proteins are lipid-modified and can act as stem cell growth 
factors. Nature 423, 448-452, doi:10.1038/nature01611 (2003). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
Acknowledgments: 
The research was funded/supported by the NIHR Clinical Research Facility at Guy’s & St 
Thomas’ NHS Foundation Trust and NIHR Biomedical Research Centre based at Guy's and St 
Thomas' NHS Foundation Trust and King's College London. Medical Research Council 
(MRC) (MGSBACR), United Kingdom; National Institutes of Health (R01AI099245 and 
U19AI109662). We are grateful to the BRC Flow Cytometry Facility, KCH NHS Foundation 
Trust for advice and technical assistance. The views expressed are those of the author(s) and 
not necessarily those of the NHS, the NIHR or the Department of Health. The project has 
received funding from the European Union's Horizon 2020 Research and Innovation 
Programme under the Marie Sklodowska-Curie grant agreement number 705607. We would 
also like to thank Prof Fiona Watt, Simon Broad and Eamonn Morrison for their support. 
Several figures were created using Servier Medical Art templates, which are licensed under a 
Creative Commons Attribution 3.0 Unported License; https://smart.servier.com. 
 
Author Contributions: 
S.T.R., J.S., H.N., and S.Q designed the study. J.S., D.K., S.S.N., M.P.S., B.O., S.B., A.K. and 
R.S conducted experiments. R.Y., A.B., S.D. and D.J.W harvested and processed tissue for 
scRNA-seq analysis. J.S, D.J.W, G.K., G.E., A.V. and S.T performed computational analysis. 
J.S., D.K., S.S.N., M.P.S., R.M. and T.V performed histology. J.S., D.K., D.J.W., S.S.N., 
M.P.S., B.O. and S.T.R analyzed and interpreted the data. J.S, D.K. and S.T.R prepared the 
manuscript with critical revision from all authors. 
 
Competing interests 
The authors declare no competing interests relevant to the study presented here. 
CD235a-/CD45-
EpCAM+/NCAM- EpCAM+/NCAM+ EpCAM+ ASGPR1+/EpCAM-
Human foetal liver Human adult liver
CD235a-
EpCAM+-
ASGPR1+/EpCAM-
EpCAM+/NCAM+
EpCAM+/NCAM-
CD235a-/CD45-
Foetal
Adult
Pr
og
en
ito
r
 m
ar
ke
rs
Fo
et
al
 h
ep
at
ic
 
m
ar
ke
rs
 
H
ep
at
ic
 m
ar
ke
rs
 
M
at
ur
e
 h
ep
at
oc
yt
e 
Fo
et
al
he
pa
to
cy
te
 
B
EC
Fo
et
al
 H
H
yP
B
EC
 m
ar
ke
rs
A
du
lt 
H
H
yP
Adult
 hepatocyte
Adult
 HHyP
Foetal
 Hepatocyte
Foetal
HHyP
BEC
AL1
AL2
AL3
FL1
FL2
FL3
FL4
FL5
100% -
75% -
50% -
25% -
0% -Foetal
 Hepatocyte
Foetal
 HHyP
Adult
Hepatocyte
Adult
HHyP
BEC
NPCs
a b
c d
e f
Log10(TPM)
 30 
 
 
Figure legends: 
Figure 1: 
ScRNA-Seq analysis of foetal and adult human liver. a Overview of foetal and adult liver 
FACS strategy. b 2D t-SNE visualisation of single cells isolated from foetal and adult human 
liver coloured by FACS gating population, shaped by tissue source. c Transcript expression of  
selected markers overlaid on the 2D t-SNE space of human liver scRNA-seq analysis. 
Expression is Log10(TPM). d Heat maps of selected gene expression in mature hepatic, foetal 
hepatic, hybrid hepatobiliary progenitor (HHyP) and mature cholangiocyte cell populations. 
Gene expression in Log10(TPM). Mean gene expression of cells in each cluster is plotted, 
HHyP population = 138 cells, Mature cholangiocyte = 9 cells, Mature hepatocytes = 226 cells, 
foetal hepatocytes = 82 cells). e 2D t-SNE visualisation of single cells isolated from foetal and 
adult human liver coloured by cell type. Phenotypic labelling based on transcriptional analysis.  
f Proportions of tissue sample contributions from adult liver (AL) and foetal Liver (FL) in each 
phenotypically labelled cell type as a percentage of the total population. t-SNE: t-distributed 
stochastic neighbor embedding. TPM: Transcripts per Million. FACS: Fluorescence-activated 
cell sorting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foetal hepatocyte Foetal HHyP Adult HHyP
KRT7
TROP2
CLDN4
CLDN10
CXCL2
MUC6
SPP1
KRT19
STAT1
HNF1B
SOX9
CDH6
CAV1
MCAM
CFTR
CXCL1
MMP7
CYP2C8
STAT4
CLDN6
WNT2B
NCAM1
HNF4A
BMP4
AFP
DLK1
GPC3
ASGR1
CYP3A7
SERPINA6
ALB
Log10(TPM)
0 1 2 3 4
 31 
 
 
 
 
Figure 2:  
Comparison of foetal hepatic and HHyP scRNA-seq populations. Heat map of selected 
gene expression in foetal hepatic, foetal hybrid hepatobiliary progenitor (HHyP) and adult 
HHyP cells. Gene expression in Log10(TPM). TPM: Transcripts per Million. 
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Figure 3:  
 
Comparison of ALB+ cells in human liver scRNA-seq populations. a 2D t-SNE visualisation 
of ALB+ cells isolated from foetal and adult human liver coloured by tissue type (left panel) 
and Kmeans cluster (right panel). Phenotypic labelling based on transcriptional analysis.  b 
Comparison of foetal and adult hepatobiliary hybrid progenitors (HHyP) significantly enriched 
genes (FC 1.1, pval <0.05 with student t-test) by venn diagram with top 10 highly expressed 
genes in foetal (left) and adult  (right) HHyPs.  c Gene set enrichment analysis (GSEA) of 
foetal vs adult HHyPs for Gene ontology (GO) terms ‘Stem cell proliferation ‘Developmental 
cell growth, ‘Homophilic cell adhesion via plasma membrane adhesion molecules’ and 
‘Extracellular matrix component’. d Transcript expression of  selected markers overlaid on the 
2D t-SNE space of human liver scRNA-seq analysis for adult HHyP restricted genes (top), 
foetal HHyP restricted genes (middle) and other cell type-specific expression patterns (bottom). 
Expression is Log10(TPM). e Heatmap of  top foetal HHyP up regulated genes in publicly 
available sequencing data from human hepatic liver progenitor cells (hepLPCs-Heps, 
GSE105019) converted from primary hepatocytes (Fu et al 2018)16. Heatmap shows expression 
in Primary Hepatocytes (pH) and human primary hepatocytes converted into liver progenitor-
like cells (HepLPCs) at different stages in transition and expansion medium (TEM). The 
colour bar indicates gene expression in log10 scale. t-SNE: t-distributed stochastic neighbor 
embedding. TPM: Transcripts per Million. FC: fold change. 
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Figure 4:  
 
TROP2- foetal HHyPs are restricted to the ductal plate of foetal liver. a RNA-ISH for 
CDH6 and STAT1 on human 2nd trimester (15-21 pcw) foetal liver ductal plate (DP) and bile 
ducts (BD) regions. Scale bars represent 50 µm. b Immunofluorescence (IF) staining of CDH6 
(yellow), CLDN3 (magenta) and STAT1 (grey) co-expression in human foetal liver slides. 
Slides counterstained in DAPI (cyan). DP and BD structures outlined in white. Scale bars 
represent 25 µm. c Immunohistochemistry (IHC) of EpCAM, CK19, CDH6 and STAT1 in BD 
and DP regions of human foetal liver. Scale bars represent 50 µm. d Duplex RNA-ISH for 
CDH6(red)/STAT1(blue) and TROP-2(red)/STAT1(blue) in foetal liver BD and DP structures. 
Scale bars represent 50 µm. Scale bars of zoomed in region represent 25 µm. e Phase contrast 
imaging and IF of foetal intra-hepatic organoids (f-IHOs) derived from EpCAM enriched foetal 
liver cells in liver expansion (LE) media. All structures are counterstained with DAPI (blue). 
All staining performed between passages 3-5. f Schematic and IF staining of f-IHOs cultured 
for 7 days in hepatic differentiation (HD media) and biliary differentiation (BD media).  All 
staining performed between passages 3-5. Images representative of n=3 foetal liver 
differentiation experiments.  
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Figure 5:  
 
In vivo lineage potential of human foetal HHyPs. a Experimental strategy for isolation and 
in vivo characterisation of foetal hepatobiliary hybrid progenitors (HHyPs) by transplantation 
beneath the renal capsules of immunodeficient NOD scid gamma (NSG) mice. b 2D t-SNE 
visualisation of single cells isolated from foetal human liver coloured by FACS gating 
population (left panel) and transcript expression of  ALB and MCAM overlaid on the 2D t-
SNE space of human foetal liver scRNA-seq analysis (right panel). Expression is Log10(TPM). 
c Gating scheme for the isolation of distinct foetal human liver populations based on expression 
of CD235a, CD45, EpCAM, NCAM and MCAM. d Hematoxylin and eosin (H&E) staining in 
tissue cross-sections of implant regions 4 weeks post renal capsule transplantation of human 
foetal liver FACS populations. Scale bars represent 100 µm. e Immunofluorescence (IF) co-
staining of CK19 (green) and ALB (red) in implant regions of HHyPs post 4 weeks 
transplantation and matched control mouse adult liver. Slides counterstained in DAPI (cyan). 
Scale bar represents 25 µm. f IF staining of FAH (red) and HNF4A (green) in implant region 
of HHyPs 4 weeks post transplantation. Slides counterstained in DAPI (cyan). Scale bars 
represent 25 µm. g IF co-staining of TROP-2 (white) and ALB (red)  in implant region of 
HHyPs 4 weeks post transplantation. Slides counterstained in DAPI (cyan). Scale bars 
represent 25 µm. t-SNE: t-distributed stochastic neighbor embedding. FACS: Fluorescence-
activated cell sorting. TPM: Transcripts per Million. 
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Figure 6: 
 
Expansion of EpCAM+/NCAM+/TROP2- human foetal liver HHyPs in the renal capsule. 
a 2D t-SNE visualisation of single cells isolated from foetal and adult human liver coloured by  
TROP-2 gene expression. Expression is Log10(TPM). b Schematic of hepatic and BEC lineage 
restriction of HHyPs based on NCAM/TROP-2 expression. c Gating scheme for the isolation 
of distinct foetal human liver populations based on expression of CD235a, CD45, EpCAM, 
NCAM and TROP2. d Hematoxylin and eosin (H&E) staining in tissue cross-sections of 
explant region for 4 week post renal capsule transplantation. Scale bars represent 250 µm. e 
Immunofluorescence (IF) staining of FAH (red) in explant region of CD235a-/CD45-
/EpCAM+/NCAM+/TROP2- HHyPs 4 weeks post transplantation. Slides counterstained in 
DAPI (cyan). Scale bars represent 75 µm. t-SNE: t-distributed stochastic neighbor embedding. 
TPM: Transcripts per Million. 
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Figure 7: 
 
Collated marker expression in hepatic progenitor populations. Heatmaps of selected 
marker expression in populations identified in this study with different cohorts of liver 
progenitor-like cells,  biliary epithelial cells (BECs) and primary hepatocytes. Shown is gene 
expression patterns of publicly available sequencing data from GEO 
(https://www.ncbi.nlm.nih.gov/geo/) or literature mined. Bulk RNA-seq data sets include 
reprogrammed human hepatic liver progenitor cells (hepLPCs-Heps, GSE105019) and primary 
hepatocytes (pHs, GSE105019) from Fu et al (2018)16 and mouse hepatocyte-derived 
proliferative ducts (HepPD, Tarlow et al 2015) and biliary-derived proliferative ducts (BilPD) 
(GSE55552), Tarlow et al 2015)8. ScRNA-seq data sets include human BECs (GSE115469) 
from Macparland et al (2018)23. Expression graded as high (red) to low (blue) relative to 
individual data sets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
